Q-omics provides the consensus-scored B3GNT5 profile across patient tissues and cancer cell-line models. B3GNT5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, B3GNT5 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, B3GNT5 RNA expression shows 19,432 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where B3GNT5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for B3GNT5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes B3GNT5 survival associations across molecular data types. B3GNT5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible B3GNT5 RNA expression–survival associations across cancer types. High B3GNT5 expression shows unfavorable associations in KIRP, HNSC, MESO, UVM, ACC and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for B3GNT5 RNA expression.
This table summarizes B3GNT5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for B3GNT5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. B3GNT5 shows lower tumor expression in COAD and BRCA and higher tumor expression in HNSC, KIRC, LIHC and KIRP. The HNSC box plot shows higher B3GNT5 RNA expression in tumor versus normal tissue (log2 FC = +1.204, t-test p < 0.001).
This table shows molecular features associated with B3GNT5 in patient tissues and cancer cell lines. In patient samples, B3GNT5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, B3GNT5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LUNG_SCLC.
